Tiimataito Oy

StimLabs Launches First FDA-Cleared Human Umbilical Cord Particulate Device for Wound Management

- StimLabs announces the commercial launch of Allacor P, the first FDA 510(k) cleared medical device derived from human umbilical cord extracellular matrix for wound management applications. - The device received FDA clearance in February 2024 and was awarded an A Code in 2025, enabling expanded access to additional sites of care beyond hospitals. - Allacor P retains structural ECM components rich in hyaluronic acid and collagen I, with a unique particulate format designed to conform to irregular and complex wounds. - Clinical feedback from wound care specialists indicates dramatic patient improvement after single applications, demonstrating the device's therapeutic potential for challenging cases.